<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="235">
  <stage>Registered</stage>
  <submitdate>3/08/2000</submitdate>
  <approvaldate>3/08/2000</approvaldate>
  <nctid>NCT00006095</nctid>
  <trial_identification>
    <studytitle>Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy</studytitle>
    <scientifictitle>A Trial of Irinotecan (NSC# 616348) Plus Vincristine in Children With Solid Tumors</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>COG-P9971</secondaryid>
    <secondaryid>P9971</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Unspecified Childhood Solid Tumor, Protocol Specific</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - irinotecan hydrochloride
Treatment: drugs - vincristine sulfate

Experimental: Vincristine Sulfate 1.5 mg/m2/wk and Irinotecan - 

Experimental: Vincristine sulfate 2.0 mg/m2/wk and Irinotecan - 


Treatment: drugs: irinotecan hydrochloride


Treatment: drugs: vincristine sulfate


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression Free Survival</outcome>
      <timepoint>Length of study</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicity</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed initial diagnosis of malignant solid tumor
             refractory to conventional therapy or for which no effective therapy exists

               -  Brain tumors allowed if not on anticonvulsants

               -  Brainstem gliomas allowed without histologic diagnosis

               -  Solid lymphomas allowed

          -  No bone marrow involvement

        PATIENT CHARACTERISTICS:

        Age:

          -  1 to 21

        Performance status:

          -  Karnofsky 50-100% if over 10 years of age

          -  Lansky 50-100% if 10 years of age and under

        Life expectancy:

          -  At least 8 weeks

        Hematopoietic:

          -  Absolute neutrophil count at least 1,000/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 8 g/dL (transfusion allowed)

        Hepatic:

          -  Bilirubin no greater than 1.5 mg/dL

          -  ALT less than 5 times normal

          -  Albumin at least 2 g/dL

        Renal:

          -  Creatinine normal for age OR

          -  Glomerular filtration rate normal for age

        Other:

          -  No uncontrolled infection

          -  No other significant systemic illness

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 1 week since prior biologic therapy and recovered

          -  At least 1 week since prior growth factors

          -  No prior stem cell transplantation

        Chemotherapy:

          -  At least 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas)
             and recovered

          -  No more than 2 prior chemotherapy regimens

          -  No other concurrent cancer chemotherapy

        Endocrine therapy:

          -  Concurrent dexamethasone allowed in patients with CNS tumors provided dose is stable
             or decreasing for at least 2 weeks prior to study

        Radiotherapy:

          -  Recovered from prior radiotherapy

          -  At least 2 weeks since prior local palliative radiotherapy (small port)

          -  No prior substantial bone marrow radiotherapy

          -  No prior central axis radiotherapy

          -  No concurrent radiotherapy

        Surgery:

          -  Not specified

        Other:

          -  No concurrent anticonvulsants

          -  No other concurrent anticancer therapy or investigational agents</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Year</inclusiveminagetype>
    <inclusivemaxage>21</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2000</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>20</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2005</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Princess Margaret Hospital for Children - Perth</hospital>
    <postcode>6001 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Children's Oncology Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Phase I trial to study the effectiveness of vincristine plus irinotecan in treating
      children who have solid tumors that have not responded to previous therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00006095</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Cynthia S. Kretschmar, MD</name>
      <address>Floating Hospital for Children at Tufts - New England Medical Center</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>